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Summary Loss of bronchodilator effectiveness or tolerance has been observed with
inhaled beta-agonists but not with inhaled anticholinergic medications. Initially,
tolerance is reflected in loss of bronchial protection against stimuli followed by loss of
bronchodilator properties. However, generally such observations have been reported
in asthma. A 6-month randomized, double-dummy placebo-controlled trial comparing
tiotropium to salmeterol provided the opportunity to examine spirometric tolerance
to long-acting beta-agonists in patients with COPD. Spirometry was measured over
12 h at baseline and at days 15, 57, 116 and 169. Changes over time from baseline
were compared relative to changes observed with placebo. A total of 623 patients
participated (tiotropium¼ 209, salmeterol¼ 213, placebo¼ 201). The groups were
similar in age (mean¼ 65 years), gender (75% men), and baseline FEV1 (mean¼
1.0870.37 l [40712% predicted]). Relative to placebo, both active drugs improved
morning pre-drug, peak and average FEV1 and FVC throughout the trial. However,
from day 1 to 169, salmeterol was associated with a higher decline in average FEV1
and FVC (0–12 h) (difference from placebo: 36 and 115ml, Po0:05), which was
most prominent over the 8–12 h period (difference from placebo: 45 and 138ml,
Po0:01). Significant declines in peak FVC relative to placebo (83ml, Po0:05) but
not FEV1 (12ml) were observed with salmeterol. Tiotropium was associated with
further improvements in spirometry from days 1 to 15 and no evidence of tolerance
from day 15 to the end of the trial. In conclusion, tolerance to pharmacologic
bronchodilation occurs with long-acting beta-agonists such as salmeterol and not with
inhaled anticholinergics.
r 2003 Elsevier Science Ltd. All rights reserved.
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Introduction
Treatment for COPD involves a step-wise approach
of adding more bronchodilators over time as the
disease progresses.1,2 Therapeutic algorithms have
identified the benefits of regularly scheduled
inhaled bronchodilators in the treatment of COPD.
Inhaled medication has been recognized as the
preferred route due to the topical delivery and
favorable efficacy to side-effect profile. Several
classes of bronchodilators exist and are defined by
their mechanism of action; differences within a
class are distinguished with regard to dosing
frequency (e.g. short- vs. long-acting bronchodila-
tors). In addition to the differences in side-effect
profiles between classes of inhaled bronchodila-
tors, there may also be pharmacological differ-
ences with regard to efficacy over time.
Specifically, inhaled beta-agonists have been asso-
ciated with tolerance to their bronchoprotective
effects in asthma.3–5 There is additional informa-
tion that bronchodilator subsensitivity to short-
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acting inhaled beta-agonists occurs following
chronic treatment with long-acting beta-ago-
nists.6–8 Such phenomenon corresponds to in vitro
data indicating subsensitization at a receptor
level.8,9
While clinical evidence of tolerance has occurred
in asthma and is generally well accepted, tolerance
to chronic administration of inhaled beta-agonists
has not been adequately addressed in patients with
COPD. Documentation and investigations evaluat-
ing tolerance to bronchodilators in COPD may be
useful for clinicians who wish to incorporate this
knowledge into prescribing practices. The comple-
tion of a large 6-month clinical trial (previously
reported by Donohue et al.)10 evaluating the
effects of tiotropium, salmeterol and placebo in
patients in COPD has allowed for the opportunity to
evaluate differences in maintenance or tolerance
to pharmacologic bronchodilation between these
two major classes of medications. We, therefore,
wish to report the results of a retrospective analysis
of serial spirometric testing over 12 h in approxi-
mately 600 patients with COPD during a 6-month
treatment period.
Methods
Study design
A multicenter, multinational, randomized, parallel-
group study of 6-month duration was performed to
compare the long-term efficacy of tiotropium dry
powder inhalation capsules with salmeterol inhala-
tion aerosol and placebo in patients with COPD. A
double-dummy design was incorporated where all
patients received one capsule (tiotropium or
placebo) through the HandiHalers device once
daily and two actuations (salmeterol or placebo)
from a metered dose inhaler twice daily. Tiotro-
pium dosing was 18 mg once daily and salmeterol
dosing was 50 mg twice daily.
Patients
Patients were required to have a physician diag-
nosis of COPD and relatively stable obstructive
airways disease with a forced expiratory volume in
1 s (FEV1) p60% of predicted normal and FEV1
p70% of forced vital capacity (FVC).11 Inclusion
criteria also required patients to be at least
40 years of age and have a smoking history
exceeding 10 pack-years. Exclusion criteria in-
cluded a history of asthma, allergic rhinitis or
atopy, an elevated eosinophil count, recent
respiratory tract infection, regular daytime supple-
mental oxygen for more than 1 h per day and a
significant disease other than COPD. A significant
disease was defined as a disease that in the opinion
of the investigator would put the patient at
risk because of participation in the study or a
disease which would influence the results of the
study. The protocol was approved by Institutional
Review Boards and written, informed consent was
obtained before any study procedure was under-
taken.
Study protocol
A 2-week baseline period preceded randomization.
Clinic visits were held at –2 weeks, 0 weeks
(randomization) and at 2, 8, 16 and 24 weeks.
12-h spirometry was performed at each visit
following successful completion of the baseline
period. Spirometry was conducted prior to the start
of therapy at –60 and –10min pre-dose at the
randomization visit and at 30, 60min, 2, 3, 4, 6, 8,
10 and 12 h post-dosing using the KoKos spiro-
meter (Pulmonary Data Services, Louisville, CO,
USA). Measurements were performed according
to American Thoracic Society criteria.12 The
highest values of FEV1 and FVC measurements
were retained. Short-acting theophyllines were
withheld at least 24 h, long-acting theophyllines
at least 48 h and short-acting b2-agonists 8 h
before spirometry. Patients were allowed to con-
tinue previously prescribed regular inhaled steroids
or regular oral steroids not exceeding a dose
equivalent to approximately 10mg prednisone
daily.
Data analysis
Analysis of covariance was performed with the
baseline being used as a covariate. Baseline FEV1
was defined as the mean of the FEV1 recordings 60
and 10min prior to the first dose of study
medication. A similar calculation was performed
on all other study days; however, the calculated
value on these days will be referred to as the
trough FEV1 (i.e., FEV1 approximately 23–24 h after
the previous dose of tiotropium or 11–12 h after the
previous dose of salmeterol). All randomized
patients with data at baseline and following 2
weeks of treatments were included in analysis. For
the patients who discontinued due to worsening
(3.3% in tiotropium, 10.3% in salmeterol, and 14.9%
in placebo) the least favorable data were carried
forward to impute the missing data. For all other
patients their missing data (9.3%) were imputed by
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their last observation. In order to be able to include
the same patients at each time point in the
spirometry summaries, missing values were esti-
mated using other values recorded for the patient
on that test day. Linear interpolation between the
two adjacent measurements was used to estimate
missing spirometry values from the middle of the
profile. For values at the end of the profiles that
were missing because rescue medication was
taken, the minimum observed FEV1 value on that
test day was used as the estimate. The last
available value was used as the estimate for data
that were missing for administrative reasons
unrelated to the patient’s response to treatment.
Unless otherwise specified, data are presented as
means7standard deviation. Statistical significance
was considered at Po0:05:
Results
Demographics
Six-hundred and twenty three patients were ran-
domized. Two-hundred and nine patients received
tiotropium, 213 received salmeterol and 201
received placebo. There were no significant differ-
ences in baseline demographics among the three
treatment groups (Table 1). The mean age of the
population was 6578 years, with 75% being men.
Mean FEV1 was 1.0870.37 l (40.2712.1% pre-
dicted). There were no significant differences
among the groups according the baseline respira-
tory medication use. Approximately 66% of patients
reported taking regular inhaled steroids. The mean
FEV1 for each treatment group at screening
was: tiotropium 1.1170.39 l (41% predicted), sal-
meterol 1.0770.37 l (39% predicted) and placebo
1.0670.36 l (41% predicted).
Improvements from baseline
Both active treatments resulted in significant
improvements in trough, peak and average (0–12h)
FEV1 and FVC compared to placebo; these results
have been reported elsewhere. On day 1 (first dose),
the improvements with both active treatments were
similar. At the end of the trial the improvements in
trough, peak and average values were superior with
tiotropium vs. salmeterol. The aforementioned
results have been reported elsewhere.10
Tolerance
Tolerance was measured as the decline in response
after treatment was initiated. As the trough
response could not be observed until day 15, the
change in trough response was defined as the
change from day 15 to the end of treatment. For
the peak and average values, the change in
response was defined as the change from day 1 to
the end of treatment. As there appeared to be
increasing improvements with tiotropium from days
1 to 15, the change in peak and average response
was also evaluated for the change from day 15 to
the end of treatment.
The changes in the magnitude of responses for
FEV1 and FVC from days 1 to 169 are recorded in
Table 2; the changes from days 15 to 169 are
recorded in Table 3. From days 1 to 169, salmeterol
was associated with a higher decline in average FEV1
and FVC (0–12h) (difference from placebo: 36 and
–115ml, Po0:05) which was most prominent over
the 8–12h period (95 and –138ml for FEV1 and FVC,
Po0:01). Significant declines in peak FVC relative to
placebo (83ml, Po0:05) but not FEV1 (12ml)
were also observed with salmeterol. Tiotropium was
associated with further improvements in spirometry
from days 1 to 15 and no evidence of tolerance from
day 15 to the end of the trial.
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Table 1 Baseline demographics and patient characteristics for the tiotropium (n ¼ 209), salmeterol (n ¼ 213)
and placebo (n ¼ 201) groups.
Tiotropium Salmeterol Placebo
Age (years)* 64.577.9 64.678.1 65.677.8
Male (%) 74 75 75
Duration of
COPD (years)*
9.277.8 10.478.2 9.777.9
Smoking
(pack years)*
47725 48726 46724
FEV1 (l)* 1.1170.39 1.0770.37 1.0670.36
FVC (l)* 2.5470.71 2.5770.76 2.5870.74
FEV1/FVC* 43.679.8 42.079.5 41.378.7
*Mean7SD.
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Discussion
A full appreciation of the pharmacologic profile
of therapeutic interventions can assist prescribers
in treating patients with COPD. All classes of
bronchodilators have been shown to improve FEV1
in the treatment of COPD, although there may
be differences to the degree of improvement.
One of the properties not well documented is
that of maintenance of bronchodilation and toler-
ance to bronchodilation over time. The present
clinical study illustrates that tolerance to bronch-
odilation seen with inhaled medications differs
between classes. Specifically, the long acting
beta-agonist salmeterol was associated with
diminishment of bronchodilating effects which
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Table 2 Mean [SE] FEV1 response following 24 weeks treatment. P-values indicate statistical significance in
comparison to placebo.
Tiotropium Placebo Salmeterol
Trough response (ml):
Day 169–15 13 [13] 14 [13] 35 [13]
Peak response (ml):
Day 169–1 20 [15]** 44 [16] 56 [15]
Day 169–15 21 [13] 26 [14] 26 [13]
Average 0–4 h (ml):
Day 169–1 22 [14]* 32 [15] 50 [14]
Day 169–15 21 [12] 13 [13] 25 [12]
Average 4–8 h (ml):
Day 169–1 1 [14] 25 [15] 68 [14]*
Day 169–15 12 [13] 12 [13] 23 [13]
Average 8–12 h (ml):
Day 169–1 3 [13] 21 [14] 66 [13]*
Day 169–15 8 [13] 10 [13] 27 [13]
Average 0–12 h (ml):
Day 169–1 5 [13] 25 [14] 61 [13]*
Day 169–15 13 [12] 11 [13] 25 [12]
*Po0:05; **Po0:01:
Table 3 Mean [SE] FVC response following 24 weeks treatment. P-values indicate statistical significance in
comparison to placebo.
Tiotropium Placebo Salmeterol
Trough response (ml):
Day 169–15 19 [25] 16 [26] 70 [25]
Peak Response (ml):
Day 169–1 24 [28] 60 [30] 143 [28]*
Day 169–15 69 [26] 70 [26] 60 [27]
Average 0–4 h (ml):
Day 169–1 7 [25] 40 [27] 115 [25]*
Day 169–15 64 [23] 37 [25] 65 [23]
Average 4–8 h (ml):
Day 169–1 56 [26] 34 [28] 161 [26]**
Day 169–15 49 [24] 31 [25] 76 [24]
Average 8–12 h (ml):
Day 169–1 35 [25] 17 [27] 155 [25]**
Day 169–15 19 [23] 13 [25] 84 [23]*
Average 0–12 h (ml):
Day 169–1 31 [24] 27 [25] 142 [24]**
Day 169–15 41 [22] 23 [23] 75 [22]
*Po0:05; **Po0:01:
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was most prominent towards the end of the dosing
interval. The majority of tolerance occurred
within a few weeks. However, there seemed
to be continued diminishment of bronchodilating
effects to salmeterol over the 6 months of the
study.
The majority of information regarding tolerance
has come from studies in asthma. Early studies of
isolated human peripheral airways smooth muscle
undergoing stimulation showed concentration-
dependent tachyphylaxis to isoprenaline.13 In
addition, there is subsensitization to beta2-recep-
tors in vitro.8,9 Clinical data support the in vitro
studies. O’Connor et al. observed that 7 days
treatment with a short-acting beta-agonist (terbu-
taline) reduced the protection against methacho-
line-induced bronchoconstriction and eliminated
the protection against AMP in patients with
asthma.3 Cockcroft et al. noted reduced pro-
tection against an allergen challenge following
chronic dosing with albuterol.5 Similar attenuation
of bronchoprotection has also been observed
with salmeterol administered to patients with
asthma.4 Simons et al. documented tolerance
to the bronchoprotective effect of salmeterol
to an exercise stimulus in asthma has also
been documented.14 Of note, the bronchoprotec-
tive effect waned towards the end of the dosing
interval but not at 1 h. The present investigation
documented that the most prominent evidence of
tolerance also occurred toward the end of the
dosing interval.
Investigators have examined whether inhaled
steroids may counteract the tolerance that has
been observed with inhaled beta-agonists with
asthma. In vitro data suggest that desensitization
can be at least partially reversed by corticoster-
oids.15,16 However, clinical studies indicate that
inhaled steroids do not protect against toler-
ance.14,17 Our data is consistent with such reports
in that tolerance to salmeterol in patients with
COPD occurred despite 2/3 of the population
receiving inhaled corticosteroids although the
doses varied and were not standardized within
the population.
The maintenance of acute responses to short-
acting inhaled beta-agonists has been evaluated
following chronic treatment with long-acting beta-
agonists. Both salmeterol and formoterol induce
significant bronchodilator subsensitivity to re-
peated doses of albuterol in some studies but not
in others.6,7,18,19 In a study of 12 patients with
asthma, the subsensitivity could be partially
reversed by a large single dose of intravenous or
inhaled corticosteroid.7 Overall the body of evi-
dence favors tolerance to beta-agonists occurring
with chronic administration in asthma. There is
sparse information as to whether there are un-
favorable effects of chronic administration of beta-
agonists in patients with COPD. In a 2-year study of
patients with moderate asthma or chronic bron-
chitis, regular administration of bronchodilators
was associated with an increase in the rate of
decline in lung function compared to as-needed
use.20 However, these results have not been
confirmed.
It is possible that due to the different patho-
genic mechanisms involved in bronchoconstriction
in COPD compared to asthma, that tolerance to
beta-agonists may not occur or that the magnitude
of tolerance may be different. Controlled clinical
studies in patients with COPD examining up to 4
months treatment with formoterol or salmeterol
have suggested that tolerance does not appear to
occur although specific analyses addressing the
issue were not reported.21,22 Laboratory-based
testing of protection against induced bronchocon-
striction in COPD have not been reported but may
not be an appropriate evaluation for tolerance in
patients with COPD.
Although diminishment of the bronchodilation
observed with salmeterol was observed by day 15,
the changes appeared to progress with time, i.e.
there was further loss of the bronchodilator effect
from days 113 to 169. The clinical results are
inconsistent with in vitro observations that toler-
ance occurs rapidly. The explanation for the
observation remains unclear. However, the magni-
tude of the diminishing bronchodilator effect of
salmeterol was relatively small; several of the
variables analyzed were not statistically signifi-
cant. It is likely that these small decrements in lung
function over time would not be detected clinically
by patients other than under unusual circum-
stances.
The present study indicated that diminishment
of FEV1 and FVC responses, particularly at the
end of the dosing interval (i.e. 8–12 h post-dose)
does occur in COPD patients treated with salmeter-
ol. It is unclear as to why tolerance was exhibited
in this study and not in previously published
COPD clinical trials with salmeterol or formoterol.
Several possibilities exist. First, the population
under study could be different. While in all
studies, there are slight nuances to the inclusion
and exclusion criteria generally all have attempted
in a reasonable fashion to include stable COPD
with documented airflow limitation and exclude
asthma. Second, there may be differences in
the degree of tolerance based on responsiveness
to acute administration of a short-acting agent.
There is variability in the magnitude of response
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of beta-agonists on a given day between patients.
Although in some studies, a sub-analysis has
been performed based on initial acute bronchodi-
lator response to an inhaled short-acting beta-
agonists (albeit not with regard to tolerance),
generally, the studies have not excluded patients
on their basis of magnitude of response. This
hypothesis cannot be evaluated as an assess-
ment of acute bronchodilation following inhalation
of a short-acting beta-agonist was not performed in
this study. Third, the analysis plan may have
differed among the studies. None of the previous
studies had specifically targeted declines in re-
sponse at the end of dosing period as in the present
analysis. Fourth, the duration of the study may
have influenced the ability to discern tolerance.
Although, on a cellular level, tolerance occurs
within a week and can occur clinically within 24 h,
we have observed that progressive changes do
appear to occur over longer periods of time. The
other studies were of shorter duration, but this is
likely an inadequate explanation. Fifth, none of the
studies, including the present study specifically set
out to evaluate tolerance as the primary outcome.
Hence, ideally a study designed that targets
pharmacologic tolerance would be of interest.
In summary, albeit relatively small, diminishment
of bronchodilator responses and duration of
bronchodilation over time was observed in patients
with COPD during chronic administration of salme-
terol 50 mg bid delivered by a metered dose in-
haler but not with tiotropium 18 mg b.i.d. delivered
by the HandiHalers. Although most of the observed
tolerance with salmeterol appeared within a few
weeks of chronic administration, further evidence
of diminished effectiveness was observed over
months of treatment. While tolerance in a COPD
clinical trial has not previously been reported, the
reasons for this observation being different from
other reported trials remains speculative. Given
the discrepant information, the data presented
should be confirmed in a prospective trial designed
specifically to examine for tolerance. Additional
information may also be gleaned through trials
evaluating bronchoprotective effects of chronic
treatment with inhaled beta-agonists in patients
with COPD. Nevertheless, the concept of tolerance
may need to be considered when re-evaluating
COPD patients during chronic treatment with long-
acting beta-agonists.
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